Lipika Goyal
Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs.
Overview
Lipika Goyal was principal investigator of FOENIX-CCA2, which won futibatinib approval for FGFR2 fusion-positive cholangiocarcinoma, and used serial ctDNA to describe the polyclonal FGFR2 kinase domain mutations that drive acquired resistance to FGFR inhibitors. She directs GI oncology at Stanford and leads trials of next-generation FGFR inhibitors.
Pages like this
not linked directly; found by shared links- ProductFutibatinib
Shares FOENIX-CCA2, FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- CompanyTyra Biosciences
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- CompanyRelay Therapeutics
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
- TrialFIGHT-202
- TrialFIRST-308
- IdeactDNA-guided switching among FGFR inhibitors
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Liquid biopsy (ctDNA), Small-molecule kinase inhibitors.
- PersonScott Kopetz
Shares Liquid biopsy (ctDNA), Small-molecule kinase inhibitors and the tag targeted-therapy.
- TermIntrahepatic, perihilar, distal and gallbladder cancer